The first three factors not only confirm that patients with an NKG2A+ bias have increased immune infiltration in their tumors but also suggest that patients with an NKG2A+ bias are equipped with the proper immune machinery of dendritic cells to prime and present CD8+ T cells with tumor antigens to permit cancer cell recognition and killing. This evidence concerns the gene CD8A and cancer.